Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

IRMD earnings analysis

Filed May 1, 2026 · Our reading of the company's report

The latest report

Iradimed Corporation reported strong Q1 2026 results featuring revenue of $22.0 million and EPS of $0.45, both exceeding analyst expectations. Revenue grew 13% year-over-year, driven by robust sales of MRI compatible…

Read full summary

Iradimed Corporation reported strong Q1 2026 results featuring revenue of $22.0 million and EPS of $0.45, both exceeding analyst expectations. Revenue grew 13% year-over-year, driven by robust sales of MRI compatible medical devices, while operating cash flow nearly doubled compared to the previous year, demonstrating solid operational performance.

Read the original on SEC.gov

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $23 Operating expenses $44 Left as operating profit $33

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

Where revenue came from

The business segments reported by the company.

Devices 70.0% Disposables 22.2% Services 4.7% Amortization of extended maintenance 3.0%

Shares of the segments disclosed in this filing, largest first.

Reported figures

Earnings per share
$0.49

What stood out

  • Revenue Growth

    Q1 2026 revenue increased 13% to $22.0 million, up from $19.5 million in Q1 2025.

  • EPS Beat

    Diluted EPS was reported at $0.45, surpassing estimates of $0.44.

  • Improved Cash Flow

    Operating cash flow nearly doubled to $8.3 million, up 93% from $4.3 million year-over-year.

  • Strong Device Sales

    Revenue from MRI compatible devices grew 19% to $15.4 million, driven by high demand.

  • Reduction in Operating Expenses

    Total operating expenses as a percentage of revenue decreased to 43.6% from 48.2% year-over-year.

  • Increased Gross Margin

    Gross margin improved to 77%, up from 76% in the prior year.

What to watch

  • Pending Tariff Refunds

    Recent Supreme Court ruling on tariffs may affect cost structures; the timing and realization of refunds for incurred costs remain uncertain.

  • Market Uncertainties

    Global geopolitical tensions may impact supply chains and international market conditions, introducing risk to operations.

  • Regulatory Approvals

    Dependence on regulatory approvals for medical devices can pose significant risks to product availability and revenue.

Management's outlook

Full-year guidance remains unchanged from prior estimates.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.